LP
RARE icon

LMR Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

LMR Partners’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$210K Hold
10,000
– – ﹤0.01% 1192
2025
Q4 		$230K Buy
+10,000
New +$329K ﹤0.01% 1260
2025
Q3 		– Sell
-79,900
Closed -$2.91M – 1614
2025
Q2 		$2.91M Buy
79,900
+29,900
+60% +$1.08M 0.02% 578
2025
Q1 		$1.81M Sell
50,000
-80,100
-62% -$3.33M 0.02% 678
2024
Q4 		$5.47M Buy
130,100
+100,100
+334% +$4.97M 0.05% 364
2024
Q3 		$1.67M Buy
+30,000
New +$1.53M 0.01% 652

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

LMR Partners's RARE Position: Q1 2026 in Review

LMR Partners reduced its Ultragenyx Pharmaceutical (RARE) stake by 84% in Q1 2026, selling an estimated $410K and leaving 3,451 shares worth $72.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1280.

LMR Partners first reported a position in RARE in Q2 2021 and has held it in 4 quarters since. The position peaked at $5.96M in Q2 2024. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • LMR Partners held 3,451 shares of Ultragenyx Pharmaceutical worth $72.3K as of Q1 2026.
  • LMR Partners sold 18,223 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $410K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of LMR Partners's portfolio in Q1 2026, its #1280 holding.
  • LMR Partners first reported a position in Ultragenyx Pharmaceutical in Q2 2021 and has held it in 4 quarters since.
  • LMR Partners's Ultragenyx Pharmaceutical position peaked at $5.96M in Q2 2024.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.